Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07409506

Assessment of Informal Support Provided by Caregivers at Different Stages of Alzheimer's Disease

In France, approximately 1,200,000 people aged 65 and over suffer from Alzheimer's disease or related disorders, of which Alzheimer's disease (AD) accounts for 70% of cases. This prevalence could double by 2050. The cognitive decline and progression to functional dependence that accompany AD are associated with a decline in quality of life, an increased risk of comorbidities, institutionalization, and mortality, as well as high care costs, placing a burden on the patient, their family and friends, and the healthcare system.

Informal care, i.e., care provided by a family member or caregiver, plays an important role in the overall management of major neurocognitive disorders (NCDs) associated with AD at home. In France, the annual cost of informal care for AD was estimated in 2008 at around €14 billion per year, or approximately 50% of the total annual cost of AD. The economic valuation of informal care serves to inform public decision-makers not only about the cost of this resource, but also about its usefulness. The issue of resource allocation (particularly the daily allowance for family caregivers - AJPA in French) at the societal level and the sharing of private (role of caregivers) and public (role of the state and local authorities) responsibilities leads us to question the determinants of this usefulness, particularly the clinical determinants in AD patients at different stages of the disease.

The main hypothesis is that informal care varies according to cognitive decline and loss of autonomy, independently or in interaction with the number and type of the patient's comorbidities, their behavioral disorders, and the caregiver's burden.

Recruiting

Interested in participating?

Request Info

Key information

Age range

60 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital des Charpennes

Villeurbanne, 69100, France

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients from Charpennes Hospital included in the MEM-AURA cohort
  • Patients aged 60 years and older at inclusion
  • Patients with dementia due to clinically probable Alzheimer's disease, regardless of stage
  • Patients with a Mini-Mental State Evaluation (MMSE) score ≤ 26 at inclusion
  • Patients accompanied by a caregiver at inclusion

Exclusion criteria

  • - Patients or caregivers who have expressed their opposition to the study
  • Patients living in institutions or nursing homes
  • Patients protected by law (under legal protection, guardianship, or conservatorship)

Early termination Criteria :

  • Patients or caregivers withdrawing their consent to participate during the study

Treatment and study plan

" Ressources Utilisation in Dementia " (RUD) questionnaire.

Other

Questionnaire on the use of services available to patients with dementia.

Primary outcomes

  1. Informal care costs

    Time frame: At inclusion or 15 days maximum after inclusion.

    Informal care will be collected according to the " Ressources Utilisation in Dementia " (RUD) questionnaire and valued in euros using replacement cost method.

Study contacts

Contact information is provided by the study sponsor or research team.

GERVAIS F M Frédéric GERVAIS

CONTACT

[email protected]

0033 4 72 43 20 66

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: ICAD

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Feb 13, 2026
Registry last updated
Feb 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.